Life-threatening macrophage activation syndrome with neurological involvement responding to very high dose IV Anakinra

Life-threatening macrophage activation syndrome with neurological involvement responding to very high dose IV Anakinra

P27.

Bibliographic Details
Main Authors:	Kavirayani, A, Basu-Roy, R, Kadambari, S, Segal, S, Qureshi, A, Finch, R, Parsons, E, Bailey, K
Format:	Conference item
Language:	English
Published:	Oxford University Press 2018

Similar Items

Continuous IV infusion of anakinra
by: Brittney N. Saunders, et al.
Published: (2023-05-01)

Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra
by: Alessandra Meneghel, et al.
Published: (2021-01-01)

Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report
by: Boyer Erynn M, et al.
Published: (2011-08-01)

Intravenous administration of anakinra in children with macrophage activation syndrome
by: Omkar Phadke, et al.
Published: (2021-06-01)

Majeed syndrome: description of a novel mutation and therapeutic response to bisphosphonates and IL-1 blockade with anakinra
by: Roy, N, et al.
Published: (2019)

The trials of anakinra.
by: Burls, A, et al.
Published: (2004)

Intravenous anakinra for treating macrophage activation syndrome in adult onset still’s disease
by: Berivan Bitik, et al.
Published: (2024-10-01)

Macrophage Activation Syndrome Associated with Adult-Onset Still’s Disease Successfully Treated with Anakinra
by: Aswini Kumar, et al.
Published: (2016-01-01)

Life Threatening Idiopathic Recurrent Angioedema Responding to Cannabis
by: Amit Frenkel, et al.
Published: (2015-01-01)

Application of anakinra in inflammatory dermatoses
by: Xiaomei YOU, et al.
Published: (2024-01-01)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
by: Mahamid M, et al.
Published: (2011-10-01)

Possibilities for the use of anakinra in COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Anakinra in pediatric acute fulminant myocarditis
by: Louise Maunier, et al.
Published: (2022-08-01)

Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome
by: Grazia Bossi, et al.
Published: (2022-05-01)

Anakinra in a case of fever familial Mediterranean
by: Elena Ferris Villanueva, et al.
Published: (2014-09-01)

Anakinra Therapy for Non-cancer Inflammatory Diseases
by: Giulio Cavalli, et al.
Published: (2018-11-01)

Anakinra treatment for refractory cerebral autoinflammatory responses
by: Yoonhyuk Jang, et al.
Published: (2022-01-01)

Effect of anakinra on arthropathy in CINCA/NOMID syndrome
by: Kaneko Utako, et al.
Published: (2010-03-01)

Anakinra: a silver lining in COVID-19?
by: Rahul Gupta
Published: (2020-10-01)

Callous-Unemotional Traits Moderate the Relationship Between Irritability and Threatening Responding
by: Ru Zhang, et al.
Published: (2021-11-01)

Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019
by: Theresa L. Wampler Muskardin
Published: (2020-05-01)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
by: Mahamid M, et al.
Published: (2011-09-01)

Dynamics of Biomarkers in COVID-19 Patients Treated with Anakinra
by: Ralitsa Yordanova, et al.
Published: (2024-11-01)

Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis
by: Allan L Klein, et al.
Published: (2024-05-01)

Subcutaneous anakinra in the management of refractory MIS-C in France
by: Perrine Dusser, et al.
Published: (2024-02-01)

Anakinra and hepatotoxicity in pediatric rheumatology: a case series
by: Frederico Rajão Martins, et al.
Published: (2023-10-01)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
by: Rahul Gupta
Published: (2022-04-01)

Anakinra for secondary amyloidosis in an adolescent with FMF and Behcet Disease
by: Bilginer Y, et al.
Published: (2008-09-01)

Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance
by: Sofia Ajeganova, et al.
Published: (2020-11-01)

Bats respond to very weak magnetic fields.
by: Lan-Xiang Tian, et al.
Published: (2015-01-01)

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy
by: A Aiello, et al.
Published: (2023-12-01)

Acute viral exanthems
by: Kadambari, S, et al.
Published: (2017)

Glutamatergic supramammillary nucleus neurons respond to threatening stressors and promote active coping
by: Abraham Escobedo, et al.
Published: (2024-06-01)

Refractory pericarditis successfully treated with anakinra in a pediatric patient
by: Carmen García-Muñoz, et al.
Published: (2018-03-01)

Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis
by: Craig Davis Scoville, et al.
Published: (2017-01-01)

Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis
by: Sullender RT, et al.
Published: (2024-09-01)

Safety and efficacy of anakinra in hemophagocytic lymphohistiocytosis associated with acute leukemia
by: Hannah Al-Yousuf, et al.
Published: (2024-02-01)

Investigation of the Effect of Anakinra on Pentylenetetrazole-Induced Epileptic Seizures in Mice
by: Ahmet Kemal FİLİZ, et al.
Published: (2021-08-01)

Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra
by: Michele Golino, et al.
Published: (2023-04-01)